References
- Abbott A, Rueth N, Pappas-Varco S, et al (2011). Perceptions of contralateral breast cancer: an overestimation of risk. Ann Surg Oncol, 18, 3129-36. https://doi.org/10.1245/s10434-011-1914-x
- Aihara T, Tanaka S, Sagara Y, et al (2014). Incidence of contralateral breast cancer in Japanese patients with unilateral minimum-risk primary breast cancer, and the benefits of endocrine therapy and radiotherapy. Breast Cancer, 21, 284-91. https://doi.org/10.1007/s12282-012-0396-4
- Allred DC, Anderson SJ, Paik S, et al (2012). Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24. J Clin Oncol, 30, 1268-73. https://doi.org/10.1200/JCO.2010.34.0141
- Arriagada R, Rutqvist LE (1991). Adjuvant chemotherapy in early breast cancer and incidence of new primary malignancies. Lancet, 338, 535-8. https://doi.org/10.1016/0140-6736(91)91100-9
- Bessonova L, Taylor TH, Mehta RS, et al (2011). Risk of a second breast cancer associated with hormone-receptor and HER2/neu status of the first breast cancer. Cancer Epidemiol Biomarkers Prev, 20, 389-96. https://doi.org/10.1158/1055-9965.EPI-10-1016
- Cancer Research Campaign Breast Cancer Trials Group (1992). The effect of adjuvant tamoxifen: the latest results from the cancer research campaign adjuvant breast trial. Eur J Cancer, 28, 904-7. https://doi.org/10.1016/0959-8049(92)90147-T
- Chen Y, Thompson W, Semenciw R, et al (1999). Epidemiology of contralateral breast cancer. Cancer Epidemiol Biomarkers Prev, 8, 855-61.
- Early Breast Cancer Trialists' Collaborative Group (1992). Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy. Lancet, 339, 1-15-7185.
- Early Breast Cancer Trialists Collaborative Group (1998). Tamoxifen for early breast cancer: an overview of randomized trials. Lancet, 351, 1451-67. https://doi.org/10.1016/S0140-6736(97)11423-4
- Gao X, Fisher SG, Emami B (2003). Risk of second primary cancer in the contralateral breast in women treated for earlystage breast cancer: a population-based study. Int J Radiat Oncol Biol Phys, 56, 1038-45. https://doi.org/10.1016/S0360-3016(03)00203-7
- Hankey BF, Curtis RE, Naughton MD, et al (1983). A retrospective cohort analysis of second breast cancer risk for primary breast cancer patients with an assessment of the effects of radiation therapy. J Natl Cancer Ins, 70, 797-804.
- Heron DE, Komarnicky LT, Hyslop T, et al (2000). Bilateral breast carcinoma: risk factors and outcomes for patients with synchronous and metachronous disease. Cancer, 88, 2739-50. https://doi.org/10.1002/1097-0142(20000615)88:12<2739::AID-CNCR12>3.0.CO;2-J
- Horn-Ross PL (1993). Multiple primary cancers involving the breast. Epidemiol Rev, 15, 169-76.
- Howlader N, Noone AM, Krapcho M, et al (????). SEER Cancer statistics review, 1975-2009 (vintage 2009 populations), National Cancer Institute, USA.
- Kilgore AR (1921). The incidence of cancer in the second breast. J Am Med Assoc, 77, 454-7. https://doi.org/10.1001/jama.1921.02630320038011
- Krishnappa R, Chikaraddi SB, Deshmane V (2015). Primary synchronous bilateral breast cancer. Indian J Cancer, 51, 256-8.
- Lizarraga IM, Sugg SL, Weigel RJ, Scott-Conner CE (2013). Review of risk factors for the development of contralateral breast cancer. Am J Surg, 206, 704-8. https://doi.org/10.1016/j.amjsurg.2013.08.002
- Loi S, Haibe-Kains B, Desmedt C, et al (2007). Definition of clinically distinct molecular subtypes in estrogen receptorpositive breast carcinomas through genomic grade. J Clin Oncol, 25, 1239-46. https://doi.org/10.1200/JCO.2006.07.1522
- Mariana L, Coradina D, Biganzoli E, et al (1997). Prognostic factors for metachronous contralateral breast cancer: a comparison of linear Cox regression model and its artificial neural network extension. Breast Cancer Res Treat, 44, 167-71. https://doi.org/10.1023/A:1005765403093
- Mellemkjaer L, Steding-Jessen M, Frederiksen K, et al (2014, In press). Risk of contralateral breast cancer after tamoxifen use among Danish women. Ann epemiol, 24, 843-8
- Nichols HB, Berrington de Gonzalez A, et al (2011). Declining incidence of contralateral breast cancer in the United States from 1975 to 2006. J Clin Oncol, 29, 1564-9. https://doi.org/10.1200/JCO.2010.32.7395
- Parkin DM, Bray F, Ferlay J, Pisani P (2005). Global cancer statistics, 2002. CA Cancer J Clin, 55, 74-108. https://doi.org/10.3322/canjclin.55.2.74
- Phillips KA, Milne RL, Rookus MA, et al (2013). Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. J Clin Oncol, 31, 3091-9. https://doi.org/10.1200/JCO.2012.47.8313
- Rebegea L, Firescu D, Anghel R, Dumitru M (2013). Clinical and therapeutical aspects of contralateral breast cancer after treatment of breast neoplasm. J Radiotherapy Med Oncol, 19, 45-8.
- Reiner AS, John EM, Brooks JD, et al (2013). Risk of asynchronous contralateral breast cancer in noncarriers of BRCA1 and BRCA2 mutations with a family history of breast cancer: a report from the women's environmental cancer and radiation epidemiology study. J Clin Oncol, 31, 433-9. https://doi.org/10.1200/JCO.2012.43.2013
- Rusner C, Wolf K, Bandemer-Greulich U, et al (2014). Risk of contralateral second primary breast cancer according to hormone receptor status in Germany. Breast Cancer Res, 16, 4.
- Shim HJ, Kim SH, Kang BJ, et al (2014). Breast cancer recurrence according to molecular subtype. Asian Pac J Cancer Prev, 15, 5539-44. https://doi.org/10.7314/APJCP.2014.15.14.5539
- Silber JH, Rosenbaum PR, Clark AS, et al (2013). Characteristics associated with differences in survival among black and white women with breast cancer. JAMA, 310, 389-97. https://doi.org/10.1001/jama.2013.8272
- Stewart HJ (1992). The Scottish trial of adjuvant tamoxifen in node-negative breast cancer. J Natl Cancer Inst Monogr, 11, 117-20.
- Storm HH, Andersson M, Boice JD, et al (1992). Adjuvant radiotherapy and risk of contralateral breast cancer. J Natl Cancer Inst, 84, 1245-50. https://doi.org/10.1093/jnci/84.16.1245
- Storm HH, Andersson M, Boice JD, et al (1992). Adjuvant radiotherapy and risk of contralateral breast cancer. J Natl Cancer Inst, 84, 1245-50. https://doi.org/10.1093/jnci/84.16.1245
- Yadav BS, Sharma SC, Patel FD, et al (2008). Second primary in the contralateral breast after treatment of breast cancer. Radiotherapy Oncol, 86, 171-6. https://doi.org/10.1016/j.radonc.2007.10.002
- Zeichner SB, Ruiz AL , Markward NJ, Rodriguez E (2014). Improved long-term survival with contralateral prophylactic mastectomy among young women. Asian Pac J Cancer Prev, 15, 1155-62. https://doi.org/10.7314/APJCP.2014.15.3.1155
Cited by
- Outcomes of contralateral prophylactic mastectomy in relation to familial history: a decision analysis (BRCR-D-16-00033) vol.18, pp.1, 2016, https://doi.org/10.1186/s13058-016-0752-y